Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 37Gemcitabine 31Paclitaxel 28Cisplatin 28Carboplatin 27Capecitabine 27camrelizumab 25Nivolumab 24apatinib 23Oxaliplatin 21fludarabine 20Radiotherapy 20toripalimab 19Drug Therapy 18Immunotherapy, Adoptive 17pembrolizumab 16Docetaxel 16Bevacizumab 16Dexamethasone 15N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Injections 14tislelizumab 13Temozolomide 13Rituximab 13Cetuximab 13Irinotecan 12Fluorouracil 11130-nm albumin-bound paclitaxel 11anlotinib 10Trastuzumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × indibulin × Clear all
NCT01113970 2013-01-30

Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer

Alaunos Therapeutics

Phase 1/2 Unknown
60 enrolled
Breast

Breast Neoplasms

NCT00726687 2012-07-19

Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors

Alaunos Therapeutics

Phase 1/2 Unknown
7 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡